Table 2.
Results of meta-analysis
| Number of studies | HR | 95% CI | P value | I2 | P value | |
|---|---|---|---|---|---|---|
| OS | 8 | 2.50 | 2.03–3.09 | <0.001 | 37.1% | 0.133 |
| Type of lung cancer | ||||||
| NSCLC | 6 | 2.68 | 2.11–3.41 | <0.001 | 49.3% | 0.079 |
| SCLC | 2 | 2.02 | 1.32–3.10 | 0.001 | 0.0 | 0.979 |
| Primary treatment | ||||||
| Surgery | 2 | 2.01 | 1.36–2.96 | <0.001 | 0.0 | 0.604 |
| ICIs | 4 | 3.20 | 2.36–4.35 | <0.001 | 51.5 | 0.103 |
| Chemotherapy | 1 | 2.04 | 1.03–4.02 | 0.041 | - | - |
| PFS | 5 | 1.91 | 1.56–2.33 | <0.001 | 4.2% | 0.383 |
| CSS | 1 | 1.90 | 1.11–3.11 | 0.018 | - | - |
HR: hazard ratio; CI: confidence interval; OS: overall survival; PFS: progression-free survival; CSS: cancer-specific survival; ICIs: immune checkpoint inhibitors; NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer